Guerbet: Financial agenda for 2024

Financial agenda for 2024

Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.

Publications calendar

2023 ANNUAL REVENUE February 08, 2024, after trading

2023 ANNUAL RESULTS March 20, 2024, after trading

2024 1ST QUARTER REVENUE April 25, 2024, after trading

ANNUAL SHAREHOLDERS’ MEETING May 24, 2024

2024 2ND QUARTER REVENUE July 25, 2024, after trading

2024 FIRST HALF RESULTS September 25, 2024, after trading

2024 3RD QUARTER REVENUE October 24, 2024, after trading

 

 

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B?–?mid caps) and generated €753 million in revenue in 2022.

Contacts :

Guerbet     
Jérôme Estampes, Chief Financial Officer + 33.1.45.91.50.00 / jerome.estampes@guerbet.com
Claire Lauvernier, Group Communication Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.com

Actifin        
Marianne Py, Financial Communication + 33.1.80.48.25.31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Media Relations +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

Attachment

• Guerbet_PR Agenda 2024